Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, Florida, USA.
J Virol. 2012 May;86(9):5122-33. doi: 10.1128/JVI.05767-11. Epub 2012 Feb 29.
Resistance to nucleoside reverse transcriptase (RT) inhibitors is conferred on human immunodeficiency virus type 1 through thymidine analogue resistance mutations (TAMs) that increase the ability of RT to excise chain-terminating nucleotides after they have been incorporated. The RT mutation M184V is a potent suppressor of TAMs. In RT containing TAMs, the addition of M184V suppressed the excision of 3'-deoxy-3'-azidothymidine monophosphate (AZTMP) to a greater extent on an RNA template than on a DNA template with the same sequence. The catalytically inactive RNase H mutation E478Q abolished this difference. The reduction in excision activity was similar with either ATP or pyrophosphate as the acceptor substrate. Decreased excision of AZTMP was associated with increased cleavage of the RNA template at position -7 relative to the primer terminus, which led to increased primer-template dissociation. Whether M184V was present or not, RT did not initially bind at the -7 cleavage site. Cleavage at the initial site was followed by RT dissociation and rebinding at the -7 cleavage site, and the dissociation and rebinding were enhanced when the M184V mutation was present. In contrast to the effect of M184V, the K65R mutation suppressed the excision activity of RT to the same extent on either an RNA or a DNA template and did not alter the RNase H cleavage pattern. Based on these results, we propose that enhanced RNase H cleavage near the primer terminus plays a role in M184V suppression of AZT resistance, while K65R suppression occurs through a different mechanism.
核苷逆转录酶(RT)抑制剂的耐药性是通过胸腺嘧啶类似物耐药突变(TAMs)赋予人类免疫缺陷病毒 1 型的,这些突变增加了 RT 在掺入终止核苷酸后切除链终止核苷酸的能力。RT 突变 M184V 是 TAMs 的有效抑制剂。在含有 TAMs 的 RT 中,与具有相同序列的 DNA 模板相比,M184V 的添加更能抑制 3'-脱氧-3'-叠氮胸苷单磷酸(AZTMP)在 RNA 模板上的切除。无催化活性的 RNase H 突变 E478Q 消除了这种差异。无论使用 ATP 还是焦磷酸作为受体底物,切除活性的降低都是相似的。AZTMP 切除活性的降低与相对于引物末端在位置-7 处对 RNA 模板的切割增加有关,这导致引物-模板解离增加。无论是否存在 M184V,RT 最初都不会结合在-7 切割位点。在初始位点的切割后,RT 解离并重新结合在-7 切割位点,当存在 M184V 突变时,解离和重新结合得到增强。与 M184V 的作用相反,K65R 突变在 RNA 或 DNA 模板上以相同的程度抑制 RT 的切除活性,并且不改变 RNase H 切割模式。基于这些结果,我们提出在引物末端附近增强的 RNase H 切割在 M184V 抑制 AZT 耐药中起作用,而 K65R 抑制则通过不同的机制发生。